Track cost pressure
Identify presentations with rising spend and create intervention plans focused on switching opportunities or formulary alignment.
Explore British National Formulary presentations, drill into dispensing trend data, and identify which pharmacies drive the greatest usage of each medicine.
Active filters
| Presentation | Product | Chemical substance | Chapter | Items dispensed |
|---|---|---|---|---|
|
Pramipexole 88microgram tablets
0409010W0AAACAC
|
Pramipexole | Pramipexole | Central Nervous System | 57,415 |
|
Pramipexole 180microgram tablets
0409010W0AAABAB
|
Pramipexole | Pramipexole | Central Nervous System | 24,245 |
|
Pramipexole 350microgram tablets
0409010W0AAADAD
|
Pramipexole | Pramipexole | Central Nervous System | 10,013 |
|
Pramipexole 260microgram modified-release tablets
0409010W0AAAEAE
|
Pramipexole | Pramipexole | Central Nervous System | 4,209 |
|
Pramipexole 520microgram modified-release tablets
0409010W0AAAFAF
|
Pramipexole | Pramipexole | Central Nervous System | 3,850 |
|
Pramipexole 700microgram tablets
0409010W0AAAAAA
|
Pramipexole | Pramipexole | Central Nervous System | 3,224 |
|
Pramipexole 1.05mg modified-release tablets
0409010W0AAAGAG
|
Pramipexole | Pramipexole | Central Nervous System | 2,496 |
|
Pramipexole 1.57mg modified-release tablets
0409010W0AAAJAJ
|
Pramipexole | Pramipexole | Central Nervous System | 1,437 |
|
Pramipexole 2.1mg modified-release tablets
0409010W0AAAHAH
|
Pramipexole | Pramipexole | Central Nervous System | 1,287 |
|
Pramipexole 3.15mg modified-release tablets
0409010W0AAAIAI
|
Pramipexole | Pramipexole | Central Nervous System | 846 |
|
Pramipexole 2.62mg modified-release tablets
0409010W0AAAKAK
|
Pramipexole | Pramipexole | Central Nervous System | 595 |
Link medicine usage to pharmacy and prescriber behaviour to find optimisation opportunities.
Identify presentations with rising spend and create intervention plans focused on switching opportunities or formulary alignment.
Cross-reference high-volume medicines with local health priorities and prescriber activity to target support programs.